SEC Form 4 · accession 0000899243-17-008162
Whitehawk Therapeutics, Inc. · WHWK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Caley Castelein
Director
Period of report
Mar 15, 2017
Accepted (ET)
Mar 17, 2017 · 8:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422142
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 15, 2017 | P | 400,000 | $5.00 | A | 1,611,408 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of (i) 392,005 shares of Common Stock owned directly by Kearny Venture Partners, L.P., or KVP, and (ii) 7,995 shares of Common Stock owned directly by Kearny Venture Partners Entrepreneurs Fund, L.P., or KVPE. The general partner of both KVP and KVPE is Kearny Venture Associates, L.L.C., or KVA. KVA has the sole voting and investment control over the shares owned by KVP and KVPE, and the Managing Members of KVA share in the voting and investment control over such shares controlled by KVA. The Managing Members of KVA are Caley Castelein, Richard Spalding and James Shapiro. None of the Managing Members of KVA has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.